Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
Á¦¸ñ 2017 ´ëÇÑÆó¾ÏÇÐȸ Ãß°èÇмú´ëȸ ¾È³»
±â°£ 2017.11.23 - 2017.11.24
±Û¾´ÀÌ °ü¸®ÀÚ
÷ºÎÆÄÀÏ
ÇмúÇà»ç ¾È³»
ÀϽÃ: 2017³â 11¿ù 23ÀÏ (¸ñ) ~ 24ÀÏ (±Ý)
Àå¼Ò: Lotte Jamsil Hotel Sapphire room
¿¬¼öÆòÁ¡: 12Á¡ (ºÎºÐÆòÁ¡ ÀÎÁ¤)
ȨÆäÀÌÁö : http://www.lungca.or.kr/abstract/2017_fall/
»çÀüµî·Ï
»çÀüµî·Ï ¸¶°¨ÀÏ: 2017³â 11¿ù 13ÀÏ(¿ù)±îÁö ¿¬Àå
ÀÚ¼¼ÇÑ ³»¿ëÀº »çÀüµî·Ï ¾È³» ¸Þ´º¸¦ Âü°í ÇϽñ⠹ٶø´Ï´Ù.
ÇÁ·Î±×·¥
Nov, 23rd (Thu)
Crystal 1Crystal 2Crystal 3
08:30-08:50Registration
08:50-09:00Opening Remark
 Session I-1.NGS
ÁÂÀå : À̰DZ¹ (±¹¸³¾Ï¼¾ÅÍ)
Session I-2. Lung cancer genomicsÁÂÀå : Àå¼¼Áø (¿ï»êÀÇ´ë)
09:00-09:20NGS±â¹Ý À¯ÀüÀÚ ÆÐ³Î°Ë»çÀÇ Áú°ü¸®¼Õ´ë¼ø (»ï¼ºÀ¯Àüü ¿¬±¸¼Ò)09:00-09:30 NGS data -based Artificial Intelligence Model for Cancer-Drug-Response Profiling Á¤Á¾¼± (½ÅÅ×Ä« ¹ÙÀÌ¿À)
09:20-09:40 NGS ±â¹Ý À¯ÀüÀÚ ÆÐ³Î °Ë»ç ±Þ¿©È­ ¹è°æ ¹× Àü¸Á½ÉÈ¿¼· (¿¬¼¼ÀÇ´ë)09:30-10:00 Study for cancer genomics; whats left?±èÁÖÇÑ (¼­¿ï´ë)
09:40-10:00 NGS ±â¹Ý À¯ÀüÀÚ ÆÐ³Î °Ë»çÀÇ ±â°üº° »óȲ ¹× Àü¸Á I±èÁöÈÆ (¿ï»êÀÇ´ë)10:00-10:30 Genomic data sharing; implications & hurdlesÁ¤¿¬ÁØ(°¡Å縯ÀÇ´ë)
10:00-10:20 NGS ±â¹Ý À¯ÀüÀÚ ÆÐ³Î °Ë»çÀÇ ±â°üº° »óȲ ¹× Àü¸Á II±èÅÂÁ¤ (°¡Å縯ÀÇ´ë) 
10:20-10:30Q&A 
10:30-11:00Coffee Break
 Plenary Session ÁÂÀå : Á¶¹®ÁØ (Ãæ³²ÀÇ´ë)
11:00-11:50The Healthcare Innovation for the precision cancer medicine with IBM Watson Health? Annette Hicks (Watson Health, IBM)
11:50-12:00Q&A
 Luncheon Symposium IÁÂÀå : ±è»óÀ§ (¿ï»êÀÇ´ë)
12:00-12:40Big Stride in 1L NSCLC treatment: moving from chemotherapy to anti- PD 1 therapy (MSD)Raffaele Califano
(The Christie NHS Foundation Trust and University Hospital of South Manchester)
12:40-13:00Coffee Break
 Oral Presentation
13:00~13:10Chemopreventive effect of long-term use of low-dose aspirin on lung cancer risk A nationwide study considering competing risk
õÀº¹Ì (ÀÌÈ­ÀÇ´ë)
13:00~13:10Weekly Docetaxel as first-line chemotherapy in elderly patients with advanced squamous cell non-small cell lung cancer : phase II study
ÃÖÁ¾Çö (°í·ÁÀÇ´ë)
13:00~13:10Æó¾Ï ȯÀÚ¸¦ ´ë»óÀ¸·Î °³ÀÎ ¸ÂÃãÇü È£Èí ÀçȰ ¼­ºñ½º(¼ûư PHR¢ç)ÀÇ ÀÓ»óÀû È¿°ú¸¦ È®ÀÎÇϱâ À§ÇÑ ÀüÇâÀû ¿¬±¸
Áö¿øÁØ (¿ï»êÀÇ´ë)
13:10~13:20Bone Metastasis is associated with Osteoporosis Risk Among Lung Cancer Patients
À̽·æ (°í·ÁÀÇ´ë)
13:10~13:20Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer
¹Ú¼ÛÀÌ (¼º±Õ°üÀÇ´ë)
13:10~13:20Generative Model of Functional RT-Plan Chest CT for Lung Cancer Patients Using Machine Learning Algorithm
Àå¹ü¼· (¼­¿ïÀÇ´ë)
13:20~13:30Role of low-dose computerized tomography in lung cancer screening among never-smokers
°­Çý¸° (¼­¿ïÀÇ´ë)
13:20~13:30Clinical characteristics of lung cancer with programmed death-ligand 1 expression
¹ÚÇÏ¿µ (Àü³²ÀÇ´ë)
13:20~13:30Generation of predicted tumor-regression computed tomography image during definitive concurrent chemo-radiotherapy of the lung cancer using deep learning technique
±è°æ¼ö (µ¿³²±Ç¿øÀÚ·ÂÀÇÇпø)
13:30~13:40Comparison of PD-L1 Expression on Cell Block and Matched Resection Specimens from Lung Cancer
³ë¹Ì¼÷ (µ¿¾ÆÀÇ´ë)
13:30~13:40Continuing Gefitinib beyond progression in patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A phase II single-arm prospective trial
ÀÓ¼º¿ø (¼º±Õ°üÀÇ´ë)
13:30~13:40Initial PET/CT maximal SUV as a Biologic Predictive Factor Prognostic of Outcome in Early-stage NSCLC after SABR
°ûÀ¯°­ (°¡Å縯ÀÇ´ë)
13:40~13:50Extracellular vesicle DNA for liquid biopsy
ÇãÀ翵 (°Ç±¹ÀÇ´ë)
13:40~13:50Outcomes of T790M+ lung cancer patients treated with osimertinib in real world practice after acquired resistance to the previous EGFR-TKI in Korea
¿Àµ¿±Ô (¿ï»êÀÇ´ë)
13:40~13:50Exosomes Increase More at Pulmonary Vein than Peripheral Vessel in Lung Cancer: based on preclinical and clinical studies
±èÇö±¸ (°í·ÁÀÇ´ë)
13:50~14:00Detection and dynamic change of EGFR mutation status in plasma and comparison of tissue from NSCLC patients
ÀÌÀ±°æ (¿ï»êÀÇ´ë)
13:50~14:00Phase II Trial of AZD9291 in Second-Line Treatment after Acquired Resistance with T790M Mutation Detected From Circulating Tumor DNA (LiquidLung-O-Cohort 2)
±è¿µÃ¶ (Àü³²ÀÇ´ë)
13:50~14:00Prognostic Factor and Survival of Patients with Resected stage IIIA N2 Lung Adenocarcinoma
±èÁ¦ÈÆ (¿ï»êÀÇ´ë)
14:00~14:10Feasibility and alternative approaches of rebiopsy in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors
±èÈñÁ¤ (°Ç±¹ÀÇ´ë)
14:00~14:10Tumor-derived microvesicles promote the immune surveillance of tumor through PD-1/PD-L1 interaction
±èµ¿ÇÏ (¿ï»êÀÇ´ë)
14:00~14:10Feasibility of lobectomy and mediastinal node dissection by video-assisted thoracoscopic surgery following neoadjuvant?chemoradiaotherapy for stage IIIA N2?lung cancer: Propensity matching analysis
Àü¿µÁ¤ (¼º±Õ°üÀÇ´ë)
14:10~14:20Feasibility of Liquid Biopsy Using Plasma and Platelets for Detection of ALK Rearrangements in Non-Small Cell Lung Cancer
¹Úö±Ô (Àü³²ÀÇ´ë)
14:10~14:20Glucose Supports EGFR-mutant Lung Adenocarcinoma Cell Survival by Inhibiting Autophagy-mediated EGFR Degradation
³ëÁø°æ (¿ï»êÀÇ´ë)
14:10~14:20Diffusing capacity(DLco) decrement following neoadjuvant concurrent chemoradiotherapy :implication on postoperative pulmonary complications in lung cancer patients
½Å¼ö¹Î (¼º±Õ°üÀÇ´ë)
14:20-14:40Coffee Break
 Session II-1. In-depth review of 8th TNM staging
ÁÂÀå : ÀÌÃáÅà (¼­¿ïÀÇ´ë)
Session II-2. Screen-detected Ground Glass NodulesÁÂÀå : ³ª±¹ÁÖ (Àü³²ÀÇ´ë)Session II-3. Emerging field of Radiomics
ÁÂÀå : ¿ëȯ¼® (°í·ÁÀÇ´ë)
14:40-15:05 TNM staging; pulmonologists
perspectiveȲº¸ºó (±¹¸³¾Ï¼¾ÅÍ)
14:40-15:00 Management strategy and guideline: follow-up vs. surgeryÀüÀçÇö (±¹¸³¾Ï¼¾ÅÍ)Basics of image processing in radiomics ±è³²±¹ (¿ï»êÀÇ´ë)
15:05-15:30 TNM staging;
radiologists perpective¾È¸íÀÓ (°¡Å縯ÀÇ´ë)
15:00-15:20 Preoperative workup: Bronchoscopy/EBUS, brain MRI, PET/ CT, Biopsy are needed?Á¶Á¤¼ö (ºÎ»êÀÇ´ë)Radiomics: the current statusÀÌÈ£¿¬ (¼º±Õ°üÀÇ´ë)
15:30-15:55 TNM staging; surgeons perspectiveÀÌÁø±¸ (¿¬¼¼ÀÇ´ë)15:20-15:40 Localization techniqueÁ¶¼®±â (¼­¿ïÀÇ´ë)Radiomics and beyond: limitations and future directions¹Úâ¹Î (¼­¿ïÀÇ´ë)
15:55-16:10Q&A15:40-16:00 Surgical procedure: Optimal extent of pulmonary resection
and mediastinal LN assessment
±èÈ«°ü (¼º±Õ°üÀÇ´ë)
Q&A
16:00-16:10Q&A 
16:10-16:40Coffee Break
 Session III-1. Neuroendocrine
tumors other than SCLCÁÂÀå : ±è°ü¹Î (¼­¿ïÀÇ´ë)
Session III-2. Thymic Epithelial Tumors
ÁÂÀå : ¿À¿µÅà (¾ÆÁÖÀÇ´ë)
Session III-3. SCLC

ÁÂÀå : ¾È¸íÁÖ (¼º±Õ°üÀÇ´ë)
16:40-17:00 Pathology of neuroendocrine tumorÇϽ¿¬ (°¡ÃµÀÇ´ë)Review of staging and pathologic classification³ë¹Ì¼÷ (µ¿¾ÆÀÇ´ë)Novel chemotherapeutic agent in SCLC±èÇý·Ã (¿¬¼¼ÀÇ´ë)
17:00-17:20 Surgery±èÇü·Ä (¿ï»êÀÇ´ë)Recent updates of chemotherapy¾ÈÈñ°æ (°¡ÃµÀÇ´ë)Role of radiation therapy in extensive disease SCLC±èÇÐÀç (¼­¿ïÀÇ´ë)
17:20-17:40Chemotherapy for large cell neuroendocrine carcinoma¼±Á¾¹« (¼º±Õ°üÀÇ´ë)Radiotherapy for Thymic Tumors¼Û»óÇõ (°­¿øÀÇ´ë)Role of surgery in SCLCÀÌÈ£¼® (ºÎ»êÀÇ´ë)
17:40-18:00Coffee Break
 Dinner Symposium (Sapphire room)ÁÂÀå : ±è¿µÃ¶ (Àü³²ÀÇ´ë)
18:00-18:50Recent update with clinical practice of Atezolizumab in NSCLC (Roche)ÇÑÁö¿¬ (±¹¸³¾Ï¼¾ÅÍ)


Nov, 24th (Fri)
Crystal 1Crystal 2Crystal 3
08:30-08:50Registration
08:50-09:00Opening Remark
 Korea-Japan Joint Symposium (Peri-operative treatment of lung cancer)ÁÂÀå : Young Tae Kim (Seoul National University ), Masahiro Tsuboi (National Cancer Center East)
 Part I
09:00-09:30Current guideline of peri-operative treatment
Hirotsugu Kenmotsu (Devision of Thoracic Oncology, Shizuoka Cancer Center)
09:30-10:00 A long debating issue; neoadjuvant vs adjuvant therapy in N2+ stage III lung cancerJhingook Kim (Sungkyunkwan University)
10:00-10:20Coffee Break
 Part I
10:20-10:50 Role of radiotherapy on peri-operative treatmentYuko Nakayama (Department of Radiation Oncology, National Cancer Center Hospital)
10:50-11:20 Application of new medical treatments such as target therapy and immunotherapy in adjuvant settingJeong Eun Lee (Chungnam National University)
11:20-11:30Wrap-up and introduction of next joint symposium in Japan
11:30-12:00General Assembly
 Luncheon Symposium IIÁÂÀå : Àα¤È£ (°í·ÁÀÇ´ë)
12:00-12:40Optimal Strategy & Recent updates in Treatment of T790M+ NSCLC (AZ)À̽·æ (°í·ÁÀÇ´ë)
12:40-13:10Coffee Break
 Session IV. Updates on Immuno-OncologyÁÂÀå : °­ÁøÇü(°¡Å縯ÀÇ´ë)
13:10-13:40Immune-related adverse effects of immunotherapyTe-Chun Hsia (China Medical University and Hospital)
13:40-14:10PD-L1 and other biomarkers in immunotherapyHo, James Chung Man (Hong Kong University)
14:10-14:40Combination strategy of immunotherapy in NSCLCRoss soo (National University Cancer Institue)
14:40-15:10Coffee Break
 Session V. Interactive session
15:10-15:50Management of multi-station or/and bulky N2-IIIA NSCLC¼±Á¾¹« (¼º±Õ°üÀÇ´ë)
 ÆÐ³Î : ÀÌ´ëÈ£ (¿ï»êÀÇ´ë), ±èÈ«°ü (¼º±Õ°üÀÇ´ë), ¾È¼ºÀÚ (Àü³²ÀÇ´ë)
15:50-16:30Approach to multifocal lung cancerÀå½ÂÈÆ (ÇѸ²ÀÇ´ë)
 ÆÐ³Î : ±è¿¬½Ç (°¡Å縯ÀÇ´ë), À̽ſ±(°æºÏÀÇ´ë), ±èÇö±¸ (°í·ÁÀÇ´ë)
16:30-16:50Award Ceremony
16:50-17:00Closing Remark

2017-11-13 ¿ÀÈÄ 4:16:34, Á¶È¸¼ö : 316